Lecithin vesicles for topical delivery of diclofenac

Eur J Pharm Biopharm. 2003 Nov;56(3):389-92. doi: 10.1016/s0939-6411(03)00143-7.

Abstract

Skin penetration of topically applied diclofenac is important for the treatment of rheumatic diseases and actinic keratoses. We have studied the permeation of diclofenac across human cadaver epidermis in-vitro from four lecithin vesicle formulations and a few marketed semi-solid preparations. The lecithin vesicle formulations were prepared by dissolving the lipid contents (lecithin and sodium cholate) in a 1:1 mixture of methanol-chloroform, evaporating the solvents under vacuum, and hydrating the lipid layer with the drug solution in water or 10% ethanol. The vesicles were sonicated for 5 min to reduce the vesicle size and their size and Zeta potential were characterized. The cumulative amount and maximum flux of diclofenac was 69.7+/-40.3 micrograms and 4.77+/-3.16 micrograms/hcm(2) from lecithin vesicles containing sodium cholate and 10% ethanol, and is the highest of all formulations studied. The cumulative amount and mean maximum flux obtained from other formulations were in the range of 2.46+/-1.98-29.9+/-10.1 micrograms and 0.53+/-0.46-3.61+/-0.86 micrograms/hcm(2). Based on the results, lecithin vesicles of diclofenac appear to be advantageous for the topical delivery of diclofenac.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Diclofenac / administration & dosage*
  • Diclofenac / pharmacokinetics
  • Diffusion Chambers, Culture
  • Drug Delivery Systems / methods*
  • Epidermis / drug effects
  • Epidermis / metabolism
  • Humans
  • In Vitro Techniques
  • Phosphatidylcholines / administration & dosage*
  • Phosphatidylcholines / pharmacokinetics

Substances

  • Phosphatidylcholines
  • Diclofenac